GnRH agonist and Letrozole
Phase 3Small molecule
GnRH agonist and Letrozole is one of 28 small molecule programs targeting Adenomyosis. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
21 competitors in Endometrial Carcinoma
#DrugCompanyPhaseTrials
1Lynparza
AstraZenecaApproved
Taxol
TevaPhase 3
Keytruda
Merck & Co.Phase 3
IC-Green
PProvepharm SAS
Approved
Megace
Bristol-Myers SquibbPhase 3
Depo-Provera
Eli LillyPhase 3
Kisqali
NovartisPhase 2
Trodelvy
GileadPhase 2
Femara
NovartisPhase 2
Afinitor
NovartisPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GnRH agonist and Letrozole. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- IIndira IVF Hospital Pvt Ltd